Contact Us    Downloads    Login  
   

              
 

Case Studies


Cenix

  • Engaged with RNAi biotech company at invitation of principal shareholders
  • Developed IM and divestment strategy to realise exit for investors
  • Divested primary technology platform to Ambion, who were the principal distributor for the company, acquired in turn by ABI, thereby returning some capital to investors and providing company a base for continued operations a final sale efforts.
  • Developed second strategic alliance programme for company for joint R&D programme and ultimate equity acquisition options
  • Developed and implemented strategy for exit of investors from remaining company

 Return to all case studies




Tel-Aviv, Israel, March 27, 2013 - Sage's client RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL) (the “Company” or “RedHill”), an emerging Israeli biopharmaceutical company focused primar...Read entire article




The Sage Group is pleased to announce that Wayne Pambianchi, Executive Director, gave an invited lecture to entrepreneurs at a European conference in Warsaw in February 2013. The video can be viewed on YouTube using the link belo...Read entire article




Barcelona, Spain – Feb 2013 – The Sage Group (www.sagehealthcare.com)  is pleased to announce its appointment by Palau Pharma S.A. as advisors to develop strategic corporat...Read entire article

Contact Us


If you are interested in contacting us or obtaining the contact details for one of our offices, please use our contact page.

If you would like to make a more comprehensive business enquiry, you can send us further details of your company using our Business Enquiry Form.


© The Sage Group 2008 Site by YouSoft   Privacy Policy   Contact us